Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Golden Throat Holdings Group Company Limited (6896.HK)
Liuzhou, CN
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.74% | -4.24% | +9.71% | -0.29% | +11.15% | -36.87% | +26.49% | +91.53% | -53.56% | -30.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-20.4% Q4'25: +29.5% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.9% Q4'25: +29.4% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.1% Q4'25: +11.8% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+32.5% ★ Q4'25: +35.8% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+26.5% ★ Q4'25: +74.2% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.73× ★ Q4'25: 0.61× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
706.92M
est: 770.37M (-8.2%)
|
768.17M
est: 921.24M (-16.6%)
|
624.08M
est: 1.12B (-44.5%)
|
694.19M
est: 1.51B (-53.9%)
|
797.13M
est: 783.68M (+1.7%)
|
646.94M
est: 897.90M (-27.9%)
|
1.19B
est: 966.01M (+22.7%)
|
943.26M
est: 923.84M (+2.1%)
|
1.20B
1.20B – 1.20B
+29.6% YoY
|
1.62B
1.62B – 1.62B
+35.0% YoY
|
799.16M
799.16M – 799.16M
-50.6% YoY
|
958.57M
958.57M – 958.57M
+19.9% YoY
|
| EBITDA |
190.47M
est: 299.68M (-36.4%)
|
168.88M
est: 358.36M (-52.9%)
|
79.42M
est: 437.56M (-81.8%)
|
160.95M
est: 585.97M (-72.5%)
|
218.16M
est: 304.86M (-28.4%)
|
233.31M
est: 349.29M (-33.2%)
|
456.65M
est: 375.15M (+21.7%)
|
337.06M
est: 358.77M (-6.1%)
|
465.07M
465.07M – 465.07M
+29.6% YoY
|
627.85M
627.85M – 627.85M
+35.0% YoY
|
310.35M
310.35M – 310.35M
-50.6% YoY
|
372.26M
372.26M – 372.26M
+19.9% YoY
|
| EBIT |
212.51M
est: 268.14M (-20.7%)
|
182.57M
est: 320.65M (-43.1%)
|
98.97M
est: 391.51M (-74.7%)
|
154.62M
est: 524.30M (-70.5%)
|
229.73M
est: 272.77M (-15.8%)
|
201.39M
est: 312.53M (-35.6%)
|
421.15M
est: 338.92M (+24.3%)
|
306.72M
est: 324.12M (-5.4%)
|
420.15M
420.15M – 420.15M
+29.6% YoY
|
567.21M
567.21M – 567.21M
+35.0% YoY
|
280.38M
280.38M – 280.38M
-50.6% YoY
|
336.31M
336.31M – 336.31M
+19.9% YoY
|
| Net Income |
154.62M
est: 187.48M (-17.5%)
|
102.91M
est: 206.61M (-50.2%)
|
61.38M
est: 237.12M (-74.1%)
|
102.19M
est: 296.20M (-65.5%)
|
167.61M
est: 78.79M (+112.7%)
|
154.05M
est: 90.82M (+69.6%)
|
318.63M
est: 216.65M (+47.1%)
|
251.20M
est: 207.19M (+21.2%)
|
252.46M
252.46M – 252.46M
+21.9% YoY
|
317.91M
317.91M – 317.91M
+25.9% YoY
|
80.35M
80.35M – 80.35M
-74.7% YoY
|
96.95M
96.95M – 96.95M
+20.7% YoY
|
| SGA |
333.74M
est: 323.61M (+3.1%)
|
388.22M
est: 386.99M (+0.3%)
|
361.77M
est: 472.51M (-23.4%)
|
355.90M
est: 632.77M (-43.8%)
|
385.99M
est: 329.21M (+17.2%)
|
336.84M
est: 377.19M (-10.7%)
|
473.04M
est: 389.24M (+21.5%)
|
410.30M
est: 372.25M (+10.2%)
|
482.55M
482.55M – 482.55M
+29.6% YoY
|
651.44M
651.44M – 651.44M
+35.0% YoY
|
322.01M
322.01M – 322.01M
-50.6% YoY
|
386.25M
386.25M – 386.25M
+19.9% YoY
|
| EPS |
0.24
est: 0.25 (-5.4%)
|
0.14
est: 0.28 (-49.9%)
|
0.08
est: 0.32 (-74.1%)
|
0.14
est: 0.40 (-65.1%)
|
0.23
est: 0.11 (+115.8%)
|
0.21
est: 0.12 (+71.0%)
|
0.43
est: 0.29 (+46.7%)
|
0.34
est: 0.28 (+21.3%)
|
0.34
0.34 – 0.34
+21.9% YoY
|
0.43
0.43 – 0.43
+25.9% YoY
|
0.11
0.11 – 0.11
-74.7% YoY
|
0.13
0.13 – 0.13
+20.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 156.3K | 0.39% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 9.7K | 0.44% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 69.2K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yong Zeng | Executive Vice Chairman of the Board & GM | 11M | male |
| Jianping Huang | Deputy GM, President of Labour Union & Executive Director | 878.3K | male |
| Jinqiang He | Deputy GM & Executive Director | 877.1K | male |
| Kexiong Zeng | Deputy GM & Executive Director | 877.1K | male |
| Pui Shan Lee | Company Secretary | — | female |
| Qiang Cheng | Chief Financial Officer & Assistant to GM | — | male |
| Wing Han Au | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6896.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
